Search

GlaxoSmithKline PLC

Uždarymo kaina

SektoriusSveikatos priežiūra

1,888 -1.44

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1887.5

Max

1899.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.2B

1.8B

Pardavimai

-989M

7.6B

P/E

Sektoriaus vid.

13.597

50.102

Pelnas, tenkantis vienai akcijai

0.465

Dividendų pajamingumas

3.5

Pelno marža

24.105

Darbuotojai

66,841

EBITDA

577M

2.8B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+10.68% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.50%

2.33%

Kitas uždarbis

2026-07-28

Kitas dividendų mokėjimo data

2026-07-09

Kita Ex Dividend data

2026-08-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3B

77B

Ankstesnė atidarymo kaina

1889.44

Ankstesnė uždarymo kaina

1888

Naujienos nuotaikos

By Acuity

46%

54%

121 / 344 reitingas Healthcare

GlaxoSmithKline PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 06:42; UTC

Uždarbis

GSK Earnings Boosted by Higher Specialty Medicine Sales

2026-05-29 09:17; UTC

Rinkos pokalbiai

GSK Hepatitis B Drug Data Beat Expectations -- Market Talk

2026-05-06 13:35; UTC

Rinkos pokalbiai

GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

2026-04-29 10:39; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

2026-04-29 10:06; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

2026-04-29 10:02; UTC

Rinkos pokalbiai
Uždarbis

GSK Makes Ideal Start for New CEO -- Market Talk

2026-04-29 06:07; UTC

Uždarbis

GSK PLC Sees 70p 2026 Dividend Payout

2026-04-29 06:07; UTC

Uždarbis

GSK PLC Declares Dividend of 17p

2026-04-29 06:07; UTC

Uždarbis

GSK PLC Free Cash Flow of GBP0.8B

2026-04-29 06:06; UTC

Uždarbis

GSK PLC Cash Generated From Operations GBP1.4B

2026-04-29 06:06; UTC

Uždarbis

GSK PLC 1Q General Medicines Sales GBP2.3B

2026-04-29 06:06; UTC

Uždarbis

GSK PLC 1Q Vaccines Sales GBP2.1B

2026-04-29 06:06; UTC

Uždarbis

GSK PLC 1Q Specialty Medicines Sales GBP3.2B

2026-04-29 06:05; UTC

Uždarbis

Analysts Saw GSK PLC 1Q Net Profit at GBP1.74B

2026-04-29 06:04; UTC

Uždarbis

Analysts Saw GSK 1Q Adjusted Operating Profit of GBP2.46B

2026-04-29 06:04; UTC

Uždarbis

GSK PLC 1Q Adjusted Operating Profit GBP2.65B

2026-04-29 06:04; UTC

Uždarbis

Analysts Saw GSK PLC Core EPS of 43.3p

2026-04-29 06:04; UTC

Uždarbis

Analysts Saw GSK PLC 1Q Turnover at GBP7.58B

2026-04-29 06:04; UTC

Uždarbis

GSK PLC 1Q Adj EPS 46.50p

2026-04-29 06:01; UTC

Uždarbis

GSK PLC Sees 2026 Adjusted EPS Growth of 7%-9%

2026-04-29 06:01; UTC

Uždarbis

GSK PLC Sees 2026 Adjusted Oper Pft Growth of 7%-9%

2026-04-29 06:01; UTC

Uždarbis

GSK PLC Sees 2026 Turnover Growth of 3%-5%

2026-04-29 06:01; UTC

Uždarbis

GSK PLC Backs 2026 View

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q EPS 42.6p

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q Turnover GBP7.63B

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q Pretax Pft GBP2.14B

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q Oper Pft GBP2.29B

2026-04-29 06:00; UTC

Uždarbis

GSK PLC 1Q Net Pft GBP1.74B

2026-04-15 06:12; UTC

Įsigijimai, susijungimai, perėmimai

GSK Completes Acquisition of 35Pharma

2026-04-10 10:43; UTC

Rinkos pokalbiai

GSK Could Report Weak General Medicines Results -- Market Talk

GlaxoSmithKline PLC Prognozė

Kainos tikslas

By TipRanks

10.68% į viršų

12 mėnesių prognozė

Vidutinis 2,082.36 GBX  10.68%

Aukščiausias 2,630 GBX

Žemiausias 1,700 GBX

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines GlaxoSmithKline PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

14 ratings

4

Pirkti

7

Laikyti

3

Parduoti

Rinkos nuotaikos

By Acuity

121 / 344 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat